Category: Regulatory Affairs
Post-Market Surveillance & Real-World Evidence: Key Priorities for Regulatory Affairs Teams
Post-market surveillance and real-world evidence: what regulatory affairs teams must prioritize Regulatory landscapes are placing stronger emphasis on vigilance after market entry. For medical device and pharmaceutical manufacturers, a proactive post-market surveillance (PMS) program and a clear strategy for real-world evidence (RWE) can mean the difference between compliant product life cycles and disruptive corrective actions.…
Read More
Global Regulatory Reliance & Convergence Playbook: Practical Strategies to Accelerate Pharma, Biologics and Medical Device Approvals
Regulatory Reliance and Convergence: Practical Strategies for Global Regulatory Affairs Regulatory reliance and convergence are reshaping how companies bring pharmaceuticals, biologics, and medical devices to global markets. As regulators increasingly recognize decisions made by trusted counterparts, organizations can streamline submissions, reduce duplication, and accelerate patient access—provided they follow a clear strategic approach. Why reliance mattersReliance…
Read More
Navigating Digital Health Regulation and SaMD: A Practical, Risk-Based Guide for Regulatory Affairs Teams
Navigating digital health regulation: practical guidance for regulatory affairs teams Digital health products and software as a medical device (SaMD) present unique regulatory challenges that require a proactive, risk-based approach. Regulatory affairs teams must balance speed to market with robust evidence, cybersecurity, and ongoing surveillance to meet both national and international expectations. The following guidance…
Read More
Regulator-Grade Real-World Evidence: 8 Essential Steps for Regulatory Teams to Accelerate Approvals
Real-world evidence (RWE) is reshaping regulatory affairs, offering a powerful complement to traditional clinical trial data. When generated and used correctly, real-world data (RWD) can accelerate approvals, support label expansions, improve safety monitoring, and strengthen market access arguments. For regulatory teams, turning RWD into robust RWE requires clear strategy, rigorous methods, and early engagement with…
Read More
Regulatory Strategies for Digital Health & AI Medical Products
Regulatory Affairs: Key Strategies for Digital Health and AI-Enabled Medical Products The regulatory landscape for digital health and AI-enabled medical products is evolving rapidly, creating both opportunity and complexity for regulatory affairs teams. Navigating approvals, maintaining compliance, and ensuring patient safety requires a proactive, evidence-driven approach that balances innovation with robust risk management. Core regulatory…
Read More
Digital Health Regulatory Strategy for SaMD: Compliance, Real-World Evidence, Cybersecurity and Market Access
The regulatory landscape for digital health products and software as a medical device (SaMD) is evolving at pace, driven by new guidance, heightened expectations for safety and performance, and growing emphasis on real-world evidence. Navigating this environment requires a clear, practical strategy that aligns product development with regulatory priorities from day one. Key regulatory pillars…
Read More
Regulatory Affairs Playbook: From Compliance to Strategic Engine for RWE, Digital Inspections & Cybersecurity
Regulatory Affairs is evolving from a checklist-driven function into a strategic engine that guides product lifecycles, market access, and patient safety. Professionals who align regulatory strategy with product development, quality, and commercial goals can accelerate approvals while reducing downstream risk. Key trends shaping regulatory work– Regulatory convergence and reliance: Regulators increasingly leverage each other’s assessments…
Read More
Regulatory Convergence: 5 Steps to Accelerate Market Access for Pharma, MedTech and Digital Health
Regulatory convergence is reshaping product development and market access strategies across pharmaceuticals, medical devices, and digital health. As regulators increasingly rely on shared assessments, harmonized guidelines, and mutual recognition, regulatory affairs teams must adapt processes to secure faster approvals while maintaining patient safety and compliance. Why convergence matters– Streamlined reviews: Reliance and mutual recognition reduce…
Read More
Building Credible Real-World Evidence (RWE) Programs: A 7-Step Regulatory Guide
Real-world evidence (RWE) is reshaping how regulators evaluate safety and effectiveness across drug, device, and biologic lifecycles. Where randomized controlled trials remain the gold standard for initial approval decisions, regulators are increasingly receptive to RWE to inform label expansions, post-market safety monitoring, and regulatory decision-making for populations underrepresented in trials. Understanding how to generate, curate,…
Read More
Regulatory Affairs Playbook: Risk-Based Strategies, Real-World Evidence & Cybersecurity to Accelerate Global Medical Product Approvals
Regulatory affairs remains a strategic pillar for organizations bringing healthcare products to market. With regulatory landscapes evolving and greater emphasis on patient safety, companies must adopt proactive, risk-based approaches that speed approval while ensuring compliance across multiple jurisdictions. Key challenges shaping regulatory strategy– Fragmented global requirements: Different regions apply varying classification rules, clinical evidence expectations,…
Read More